NeoDoppler: New Ultrasound Technology for Continuous Monitoring of Cerebral Circulation Pilot

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-12
SponsorSt. Olavs Hospital

About this trial

Non-invasive tools for monitoring of course of disease are important and necessary in the treatment of pre-term/premature infants and sick neonates. For many years, the ultrasound group in Trondheim has been at the forefront in the development of new ultrasound technology for the diagnosis and monitoring of disease. Several methods previously developed in this research group are today widely used in hospitals around the world. In this project the investigators aim to test a new ultrasound technology that allows continuous monitoring of cerebral blood flow in sick neonates and pre-term children. This technology was CE-certified in October 2022, and in this project the investigators will test the CE-certified version with the newest available approved software.

Eligibility criteria

Qualifiers

Open fontanelle

Healthy preterm or term born neonates

Neonates with a medical condition of interest according to the different cohort studies: patent ductus arteriosus, perinatal asphyxia, stroke, pulmonary hypertension, congenital heart condition or infection/sepsis/meningitis

Neonates in need of procedures

Disqualifiers

Caregivers not understanding/speaking Norwegian or English

Caregivers not giving their consent

Trial design

Treatments tested in this trial

  • NeoDoppler - CE certified

Treatment groups

180 Participants
are divided into 5 treatment groups

Sponsors and collaborators

St. Olavs Hospital

Lead sponsor

Norwegian University of Science and Technology

Collaborator